Pyxis Oncology, Inc. Research and Development Expense
Pyxis Oncology, Inc. (PYXS) reported Research and Development Expense of $16.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Pyxis Oncology, Inc. research and development expense for the quarter ending 2026-06-30 was $16.06M, a 6.28% decline year-over-year.
- Pyxis Oncology, Inc. research and development expense for the quarter ending 2026-03-31 was $19.98M, a 17.24% increase year-over-year.
- Pyxis Oncology, Inc. research and development expense for the quarter ending 2025-12-31 was $21.71M, a 54.81% increase year-over-year.
- Pyxis Oncology, Inc. research and development expense for the quarter ending 2025-09-30 was $17.81M, a 0.38% increase year-over-year.
- Pyxis Oncology, Inc. research and development expense for fiscal 2025 was $73.70M, a 25.45% increase from fiscal 2024.
- Pyxis Oncology, Inc. research and development expense for fiscal 2024 was $58.75M, a 18.47% increase from fiscal 2023.
- Pyxis Oncology, Inc. research and development expense for fiscal 2023 was $49.59M, a 42.43% decline from fiscal 2022.
- Pyxis Oncology, Inc. research and development expense for fiscal 2022 was $86.13M, a 68.70% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.06M 10-Q · filed 2026-08-13 | $36.04M 10-Q · filed 2026-08-13 | $57.75M derived: sum of 3 quarters · filed 2026-08-13 | $75.56M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $19.98M 10-Q · filed 2026-05-14 | $41.69M derived: sum of 2 quarters · filed 2026-05-14 | $59.50M derived: sum of 3 quarters · filed 2026-05-14 | $76.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $21.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $39.52M derived: sum of 2 quarters · filed 2026-03-23 | $56.65M derived: sum of 3 quarters · filed 2026-08-13 | $73.70M 10-K · filed 2026-03-23 |
| 2025-09-30 | $17.81M 10-Q · filed 2025-11-03 | $34.94M derived: sum of 2 quarters · filed 2026-08-13 | $51.98M 10-Q · filed 2025-11-03 | $66.01M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $17.13M 10-Q · filed 2026-08-13 | $34.18M 10-Q · filed 2026-08-13 | $48.20M derived: sum of 3 quarters · filed 2026-08-13 | $65.94M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $17.04M 10-Q · filed 2026-05-14 | $31.07M derived: sum of 2 quarters · filed 2026-05-14 | $48.81M derived: sum of 3 quarters · filed 2026-05-14 | $62.76M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $14.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $31.77M derived: sum of 2 quarters · filed 2026-03-23 | $45.72M derived: sum of 3 quarters · filed 2026-03-23 | $58.75M 10-K · filed 2026-03-23 |
| 2024-09-30 | $17.74M 10-Q · filed 2025-11-03 | $31.69M derived: sum of 2 quarters · filed 2025-11-03 | $44.72M 10-Q · filed 2025-11-03 | $56.33M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $13.95M 10-Q · filed 2025-08-14 | $26.98M 10-Q · filed 2025-08-14 | $38.59M derived: sum of 3 quarters · filed 2025-08-14 | $53.28M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $13.03M 10-Q · filed 2025-05-15 | $24.64M derived: sum of 2 quarters · filed 2025-05-15 | $39.32M derived: sum of 3 quarters · filed 2025-05-15 | $50.71M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $11.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $26.29M derived: sum of 2 quarters · filed 2025-03-18 | $37.69M derived: sum of 3 quarters · filed 2025-03-18 | $49.59M 10-K · filed 2025-03-18 |
| 2023-09-30 | $14.69M 10-Q · filed 2024-11-12 | $26.08M derived: sum of 2 quarters · filed 2024-11-12 | $37.98M 10-Q · filed 2024-11-12 | $67.83M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $11.39M 10-Q · filed 2024-08-14 | $23.29M 10-Q · filed 2024-08-14 | $53.15M derived: sum of 3 quarters · filed 2024-08-14 | $72.18M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $11.90M 10-Q · filed 2024-05-14 | $41.76M derived: sum of 2 quarters · filed 2024-05-14 | $60.79M derived: sum of 3 quarters · filed 2024-05-14 | $77.96M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $29.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $48.89M derived: sum of 2 quarters · filed 2024-03-21 | $66.06M derived: sum of 3 quarters · filed 2024-03-21 | $86.13M 10-K · filed 2024-03-21 |
| 2022-09-30 | $19.03M 10-Q · filed 2023-11-07 | $36.20M derived: sum of 2 quarters · filed 2023-11-07 | $56.27M 10-Q · filed 2023-11-07 | $63.50M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $17.17M 10-Q · filed 2023-08-11 | $37.24M 10-Q · filed 2023-08-11 | $44.47M derived: sum of 3 quarters · filed 2023-08-11 | $52.32M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $20.07M 10-Q · filed 2023-05-11 | $27.30M derived: sum of 2 quarters · filed 2023-05-11 | $35.15M derived: sum of 3 quarters · filed 2023-05-11 | $38.35M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $7.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $15.07M derived: sum of 2 quarters · filed 2023-03-22 | $18.28M derived: sum of 3 quarters · filed 2023-03-22 | $51.05M 10-K · filed 2023-03-22 |
| 2021-09-30 | $7.85M 10-Q · filed 2022-11-01 | $11.05M derived: sum of 2 quarters · filed 2022-11-01 | $43.83M 10-Q · filed 2022-11-01 | $46.97M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $3.21M 10-Q · filed 2022-08-15 | $35.98M 10-Q · filed 2022-08-15 | $39.12M derived: sum of 3 quarters · filed 2022-08-15 | $41.54M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $32.77M 10-Q · filed 2022-05-13 | $35.91M derived: sum of 2 quarters · filed 2022-05-13 | $38.34M derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $5.56M derived: sum of 2 quarters · filed 2022-03-29 | $9.05M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $2.42M 10-Q · filed 2021-11-15 | $5.91M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |